In the clinical trial, NCT01424865, the expression of the cancer stem cell biomarker CD44+/CD24− y ALDH1 was evaluated as a predictor of response to Trastuzumab in 1874 samples from BC patients previously treated in the NSABP-B-31 trial. Here, CD44 is linked to breast cancer.